US87650L1035 - Common Stock
TARSUS PHARMACEUTICALS INC
NASDAQ:TARS (3/28/2024, 4:02:40 PM)
After market: 36.35 0 (0%)36.35
+1.78 (+5.15%)
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 87 full-time employees. The company went IPO on 2020-10-16. The Company’s lead product candidate, TP-03, is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). The firm designs TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The company is also focused on investigating the development of product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
TARSUS PHARMACEUTICALS INC
15440 Laguna Canyon Road
Irvine CALIFORNIA 92618
P: 19494099820
CEO: Bobak Azamian
Employees: 87
Website: https://www.tarsusrx.com/
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease ...
Tarsus Pharmaceuticals faces a 10% premarket drop as it prices a $100M securities offering, consisting of shares and pre-funded warrants.
Here you can normally see the latest stock twits on TARS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: